Becton Dickinson and (NYSE:BDX) Releases FY 2019 Earnings Guidance

Becton Dickinson and (NYSE:BDX) updated its FY 2019 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $11.65-11.75 for the period, compared to the Thomson Reuters consensus estimate of $11.68. The company issued revenue guidance of $17.26164-17.42147 billion, compared to the consensus revenue estimate of $17.28 billion.

Several research analysts have issued reports on the stock. UBS Group lowered their price target on shares of Becton Dickinson and from $265.00 to $250.00 and set a neutral rating for the company in a report on Friday, May 10th. Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an equal weight rating in a research note on Tuesday, July 16th. Raymond James lifted their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a strong-buy rating in a research note on Friday, June 28th. BMO Capital Markets lowered their price objective on shares of Becton Dickinson and from $272.00 to $270.00 and set a market perform rating for the company in a research note on Friday, May 10th. Finally, Zacks Investment Research upgraded shares of Becton Dickinson and from a sell rating to a hold rating in a research note on Monday, May 20th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $264.27.

NYSE BDX traded up $2.82 during mid-day trading on Wednesday, hitting $244.96. The company’s stock had a trading volume of 1,251,519 shares, compared to its average volume of 845,774. The firm’s 50 day moving average price is $250.87. Becton Dickinson and has a twelve month low of $208.62 and a twelve month high of $265.87. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $65.23 billion, a price-to-earnings ratio of 22.25, a price-to-earnings-growth ratio of 1.84 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter last year, the firm posted $2.91 EPS. Becton Dickinson and’s revenue was up 1.7% compared to the same quarter last year. On average, analysts predict that Becton Dickinson and will post 11.68 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is currently 27.97%.

In other news, EVP Simon D. Campion sold 2,903 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total transaction of $687,836.82. Following the sale, the executive vice president now directly owns 9,408 shares in the company, valued at $2,229,131.52. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Betty D. Larson sold 1,700 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $224.97, for a total value of $382,449.00. Following the sale, the executive vice president now owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. In the last three months, insiders sold 21,154 shares of company stock valued at $4,955,775. 0.12% of the stock is currently owned by insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Net Margin

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.